Save time and money with
Med Tech Market Research


MedTech Business intelligence
supplied through Trade Tracker, Research and Markets and GlobalData

AstraZeneca plc: PharmaVitae Profile

Publication Date:  Sept 2009
Publisher: Datamonitor
Pages: 112

Price £5,700.00
approximately: $9,444 | €6,321

Summary

This analysis examines the historical and forecast performance for AstraZeneca in the Rx pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Scope

Highlights

Reasons to Purchase

  • Benchmark AstraZeneca's performance against key rivals in the prescription pharmaceutical sector
  • Assess the commercial impact of AstraZeneca's recent movement into the biologics market, spearheaded by its acquisition of MedImmune
  • Analyse the exposure of AstraZeneca's blockbuster portfolio to patent expiration and generic competition through to 2014
  • ABOUT DATAMONITOR HEALTHCARE
    • About the PharmaVitae team
  • Chapter 1 About this profile
    • PharmaVitae Explorer database
  • Chapter structure
    • Executive summary
    • Quarterly news update
    • Company introduction
    • Company sales
    • Company financials
    • Key products and competitors
    • Data sourcing
    • Sales data
    • Analyst consensus
  • Chapter 2 Executive summary
    • Key findings
    • Prescription pharmaceutical sales and growth rate performance, 2002-14
    • Financial performance, 2002-14
    • AstraZeneca: PharmaVitae forecasts at a glance
    • Strategic insight
    • Acquisition of MedImmune
    • Blockbuster-centric growth model
    • Exposure to generic competition to intensify
    • Lack of new product launches damages integrity of blockbuster strategy
    • Cost control essential to retain hope of profit growth
    • Outlook
    • SWOT analysis
    • Strengths
    • Weaknesses
    • Opportunities
    • Threats
    • Table of Contents
    • Table of figures
  • Chapter 3 Quarterly news update
    • Product developments
    • Deals and alliances
    • Product deals
    • Technology deals
    • M&A activity
    • Company announcements
    • Future product milestones
  • Chapter 4 Company introduction
    • Key findings
    • Background
    • M&A history
    • Astra AB and Zeneca Group plc
    • Subsequent M&A activity
    • Abgenix
    • Cambridge Antibody Technology (CAT)
    • KuDOS Pharmaceuticals
    • Arrow Therapeutics
    • MedImmune
    • Albireo
    • M&A strategy
  • Chapter 5 Company sales
    • Key findings
    • Prescription pharmaceutical sales and growth rate analysis, 2002-14
    • Product analysis
    • Product analysis, 2002-08
    • Product analysis, 2008-14
    • Therapy area analysis
    • Geographic analysis
    • Launch/core/expiry analysis
    • Explanation of launch/core/expiry analysis
    • Launch analysis, 2008-14
    • Core analysis, 2008-14
    • Expiry analysis, 2008-14
    • Launch/core/expiry configuration, 2008-14
    • Molecule type analysis
    • Externalization analysis
  • Chapter 6 Company financials
    • Key findings
    • Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002-08
    • Operating costs and profit analysis
    • Operating costs and profit analysis, 2002-08
    • Operating cost ratio and profit margin analysis, 2002-08
    • Operating cost ratio and profit margin analysis, 2008-14
    • Operating costs and profit analysis, 2008-14
  • Chapter 7 Key products and competitors
    • Overview
    • Cardiovascular
    • Crestor
    • Overview
    • Sales forecast
    • Product introduction
    • Potential market share gain via CRP label change
    • Competitive landscape
    • Positive impact of Zetia/Vytorin setback
    • Combination product with Abbott - Crestor + TriLipix
    • Brilinta
    • Overview
    • Sales forecast
    • Product introduction
    • Competitive landscape
    • Oncology
    • Arimidex
    • Overview
    • Sales forecast
    • Product introduction
    • Competitive landscape
    • Gastrointestinal
    • Nexium
    • Overview
    • Sales forecast
    • Product introduction
    • Competitive landscape
    • Central Nervous System
    • Seroquel
    • Overview
    • Sales forecast
    • Product introduction
    • Competitive landscape
    • Lifecycle management strategy
    • Respiratory
    • Symbicort
    • Overview
    • Sales forecast
    • Product introduction
    • Competitive landscape
    • Use of SMART concept to differentiate from Seretide/Advair
    • Emergence of new competitors in asthma/COPD market
    • Pulmicort
    • Overview
    • Sales forecast
    • Product introduction
    • Competitive landscape
    • Infectious diseases
    • Numax
    • Overview
    • Sales forecast
    • Product introduction
    • Considerable benefit over Synagis
    • Robust Phase III clinical data
    • Potential delay to US regulatory approval
    • Synagis
    • Overview
    • Sales forecast
    • Product introduction
    • Competitive landscape
    • Endocrinology
    • Onglyza
    • Overview
    • Sales forecast
    • Product introduction
    • Competitive landscape
  • Chapter 8 Appendix
    • R&D pipeline
    • Abbreviations
    • Exchange rates
    • About Datamonitor
    • About Datamonitor Healthcare
    • Datamonitor consulting
    • Disclaimer
  • List of Tables
    • Table 1: AstraZeneca - PharmaVitae forecasts at a glance
    • Table 2: AstraZeneca key product developments, Q1-Q2 2009
    • Table 3: AstraZeneca product deals and alliances, Q1-Q2 2009
    • Table 4: AstraZeneca technology deals and alliances, Q1-Q2 2009
    • Table 5: AstraZeneca M&A activity, Q1-Q2 2009
    • Table 6: AstraZeneca company announcements, Q1-Q2 2009
    • Table 7: AstraZeneca future product milestones, 2009-11
    • Table 8: AstraZeneca product portfolio overview ($m), 2002-08
    • Table 9: AstraZeneca product portfolio overview ($m), 2008-14
    • Table 10: AstraZeneca prescription pharmaceutical sales by therapy area ($m), 2008-14
    • Table 11: AstraZeneca prescription pharmaceutical sales by geographic region ($m), 2008-14
    • Table 12: AstraZeneca launch portfolio overview ($m), 2008-14
    • Table 13: AstraZeneca core portfolio overview ($m), 2008-14
    • Table 14: AstraZeneca expiry portfolio overview ($m), 2008-14
    • Table 15: AstraZeneca prescription pharmaceutical sales by molecule type ($m), 2008-14
    • Table 16: AstraZeneca prescription pharmaceutical sales by source ($m), 2008-14
    • Table 17: Total AstraZeneca sales by business unit ($m), 2002-08
    • Table 18: AstraZeneca operating revenue/cost analysis ($m), 2002-08
    • Table 19: AstraZeneca operating cost ratio analysis (% of total revenues), 2002-08
    • Table 20: AstraZeneca operating cost ratio analysis (% of total revenues), 2008-14
    • Table 21: AstraZeneca operating revenue/cost analysis ($m), 2008-14
    • Table 22: AstraZeneca Key products overview
    • Table 23: Crestor: overview
    • Table 24: Crestor: sales forecast ($m), 2008-14
    • Table 25: Brilinta: overview
    • Table 26: Brilinta: sales forecast ($m), 2008-14
    • Table 27: Arimidex: overview
    • Table 28: Arimidex: sales forecast ($m), 2008-14
    • Table 29: Nexium: overview
    • Table 30: Nexium: sales forecast ($m), 2008-14
    • Table 31: Seroquel: overview
    • Table 32: Seroquel: sales forecast ($m), 2008-14
    • Table 33: Symbicort: overview
    • Table 34: Symbicort: sales forecast ($m), 2008-14
    • Table 35: Pulmicort: overview
    • Table 36: Pulmicort: sales forecast ($m), 2008-14
    • Table 37: Numax: overview
    • Table 38: Numax: sales forecast ($m), 2008-14
    • Table 39: Synagis: overview
    • Table 40: Synagis: sales forecast ($m), 2008-14
    • Table 41: Onglyza: overview
    • Table 42: Onglyza: sales forecast ($m), 2008-14
    • Table 43: AstraZeneca R&D pipeline (Phase I-Phase III)
    • Table 44: Exchange rates, 2009
  • List of Figures
    • Figure 1: The PharmaVitae Explorer
    • Figure 2: AstraZeneca prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14
    • Figure 3: AstraZeneca's financial performance ($m), 2002-14
    • Figure 4: AstraZeneca prescription pharmaceutical sales growth by portfolio component (blockbusters, rest of portfolio, new launches) ($m), 2002-14
    • Figure 5: AstraZeneca 2008 prescription pharmaceutical sales by global launch year ($m)
    • Figure 6: AstraZeneca absolute change in sales by portfolio component ($m), 2008-14
    • Figure 7: AstraZeneca operating revenue/cost analysis ($m), 2002-14
    • Figure 8: AstraZeneca SWOT analysis
    • Figure 9: AstraZeneca prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14
    • Figure 10: AstraZeneca Key product sales ($m), 2002-14
    • Figure 11: AstraZeneca key sales growth drivers and resistors ($m), 2002-08
    • Figure 12: AstraZeneca key sales growth drivers and resistors ($m), 2008-14
    • Figure 13: AstraZeneca prescription pharmaceutical sales by therapy area ($m), 2002-14
    • Figure 14: AstraZeneca prescription pharmaceutical sales by geographic region ($m), 2002-14
    • Figure 15: AstraZeneca launch/core/expiry configuration ($m), 2008-14
    • Figure 16: AstraZeneca prescription pharmaceutical sales by molecule type ($m), 2002-14
    • Figure 17: AstraZeneca prescription pharmaceutical sales by source ($m), 2002-14
    • Figure 18: AstraZeneca operating revenue/cost analysis ($m), 2002-14

 

To top